Abstract
Intra-arterial or intravenous infusion of prostacyclin at three dose levels (2, 5, and 10 ng/kg per min) in 10 subjects without evidence of coronary heart disease or cardiac failure, led to a distinct fall in peripheral and total pulmonary vascular resistances. This was accompanied by a drop in intra-arterial blood pressure, and the acceleration of heart rate. Stroke volume, cardiac output, mean right atrial pressure, and left ventricular end-diastolic pressure showed no significant changes. Except for sporadic headache no side effects occurred. Prostacyclin appears to act predominantly on resistance vessels. The haemodynamic effects produced by prostacyclin in man might be of clinical interest in the treatment of conditions associated with a significant rise in vascular resistance.
Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Fitzpatrick T. M., Alter I., Corey E. J., Ramwell P. W., Rose J. C., Kot P. A. Cardiovascular responses to PGI2 (prostacyclin) in the dog. Circ Res. 1978 Feb;42(2):192–194. doi: 10.1161/01.res.42.2.192. [DOI] [PubMed] [Google Scholar]
- Gryglewski R. J., Bunting S., Moncada S., Flower R. J., Vane J. R. Arterial walls are protected against deposition of platelet thrombi by a substance (prostaglandin X) which they make from prostaglandin endoperoxides. Prostaglandins. 1976 Nov;12(5):685–713. doi: 10.1016/0090-6980(76)90047-2. [DOI] [PubMed] [Google Scholar]
- Gryglewski R. J., Korbut R., Ocetkiewicz A. Generation of prostacyclin by lungs in vivo and its release into the arterial circulation. Nature. 1978 Jun 29;273(5665):765–767. doi: 10.1038/273765a0. [DOI] [PubMed] [Google Scholar]
- Gryglewski R. J., Szczeklik A. Inhibition of prostacyclin formation by lipid peroxides in the arterial wall: hypothetical step in development of atherosclerosis. Mater Med Pol. 1978 Oct-Dec;10(4):338–341. [PubMed] [Google Scholar]
- Kadowitz P. J., Chapnick B. M., Feigen L. P., Hyman A. L., Nelson P. K., Spannhake E. W. Pulmonary and systemic vasodilator effects of the newly discovered prostaglandin, PGI2. J Appl Physiol Respir Environ Exerc Physiol. 1978 Sep;45(3):408–413. doi: 10.1152/jappl.1978.45.3.408. [DOI] [PubMed] [Google Scholar]
- Leffler C. W., Hessler J. R. Pulmonary and systemic vascular effects of exogenous prostaglandin I2 in fetal lambs. Eur J Pharmacol. 1979 Feb 15;54(1-2):37–42. doi: 10.1016/0014-2999(79)90405-9. [DOI] [PubMed] [Google Scholar]
- Massie B. M., Chatterjee K. Vasodilator therapy of pump failure complicating acute myocardial infarction. Med Clin North Am. 1979 Jan;63(1):25–51. doi: 10.1016/s0025-7125(16)31715-1. [DOI] [PubMed] [Google Scholar]
- Moncada S., Gryglewski R. J., Bunting S., Vane J. R. A lipid peroxide inhibits the enzyme in blood vessel microsomes that generates from prostaglandin endoperoxides the substance (prostaglandin X) which prevents platelet aggregation. Prostaglandins. 1976 Nov;12(5):715–737. doi: 10.1016/0090-6980(76)90048-4. [DOI] [PubMed] [Google Scholar]
- Nowak J. Prostaglandins in the cardiovascular system in man. A biochemical and physiological study. Acta Physiol Scand Suppl. 1979;467:1–49. [PubMed] [Google Scholar]
- Olsson A. G., Carlson L. A. Clinical, hemodynamic and metabolic effects of intraarterial infusions of prostaglandin E1 in patients with peripheral vascular disease. Adv Prostaglandin Thromboxane Res. 1976;1:429–432. [PubMed] [Google Scholar]
- Parmley W. W., Diamond G., Tomoda H., Forrester J. S., Swan H. J. Clinical evaluation of left ventricular pressures in myocardial infarction. Circulation. 1972 Feb;45(2):358–366. doi: 10.1161/01.cir.45.2.358. [DOI] [PubMed] [Google Scholar]
- Szczeklik A., Gryglewski R. J., Nizankowski R., Musiał J., Pietoń R., Mruk J. Circulatory and anti-platelet effects of intravenous prostacyclin in healthy men. Pharmacol Res Commun. 1978 Jun;10(6):545–556. doi: 10.1016/s0031-6989(78)80053-8. [DOI] [PubMed] [Google Scholar]
- Szczeklik A., Nizankowski R., Skawinski S., Szczeklik J., Gluszko P., Gryglewski R. J. Successful therapy of advanced arteriosclerosis obliterans with prostacyclin. Lancet. 1979 May 26;1(8126):1111–1114. doi: 10.1016/s0140-6736(79)91792-6. [DOI] [PubMed] [Google Scholar]
- Szczeklik J., Dubiel J. S., Mysik M., Pyzik Z., Krol R., Horzela T. Effects of prostaglandin E1 on pulmonary circulation in patients with pulmonary hypertension. Br Heart J. 1978 Dec;40(12):1397–1401. doi: 10.1136/hrt.40.12.1397. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Weissler A. M., Harris W. S., Schoenfeld C. D. Systolic time intervals in heart failure in man. Circulation. 1968 Feb;37(2):149–159. doi: 10.1161/01.cir.37.2.149. [DOI] [PubMed] [Google Scholar]